Chairs’ Symposium: Recent advances and treatments in status epilepticus

Co-chairs: Meir Bialer (Israel) & Eugen Trinka (Austria)

  • Circuits, networks, and systems in status epilepticus – Jaideep Kapur (USA)
  • Epigenetic treatment strategies – David Henshall (Ireland)
  • New and upcoming pharmacological treatments of status epilepticus – Stephan Rüegg (Switzerland)
  • Unmet needs in neonatal status epilepticus – Ronit Pressler (United Kingdom)

Acquired epilepsies: mechanisms, therapeutic advances and unmet needs

Topic Chair: Alla Guekht (Russia)

Co-chair: Dragoslav Sokic (Serbia)

  • Susceptibility and consequences of acquired epilepsies: does gender play a role? – Piero Perucca (Australia)
  • Comorbidities and the neurobiological basis for epilepsies after brain lesions – Alla Guekht (Russia)
  • Blood-brain barrier dysfunction and epileptogenesis – Alon Friedman (Israel/Canada)
  • Prevention or modification of epileptogenesis after brain insults: clinical perspective – Eugen Trinka (Austria)

Advances in the development of diagnostic and prognostic biomarkers for childhood onset epilepsies

Topic Chair: Martha Feucht (Austria)

Co-chair: Helen Cross (United Kingdom)

  • Biomarkers for seizure and developmental outcomes in early onset childhood epilepsies – lessons learned from our patients – Sergiusz Jozwiak (Poland)
  • Biomarkers for recognition of candidacy for epilepsy surgery – Helen Cross (United Kingdom)
  • Biomarkers for seizure freedom after epilepsy surgery – Julia Jacobs (Germany)
  • Prediction of seizure recurrence and long-term outcome after AED withdrawal in seizure-free patients – Kees Braun (Netherlands)

Targeted therapy

Topic Chair: Simon Shorvon (United Kingdom)

Co-chair: Heidrun Potschka (Germany)

  • Targeting genes – Renzo Guerrini (Italy)
  • Targeting novel receptors – Mike Rogawski (USA)
  • Targeting epileptogenesis – Asla Pitkanen (Finland)
  • Targeting systems – Mark Cook (Australia)

 Tauopathies and epilepsy

Topic Chair: Matthew Walker (United Kingdom) 

Co-chair: Andrew Cole (USA)

  • The physiological and pathophysiological relevance of Tau – Gabor Kovacs (Austria)
  • The role of Tau in epileptogenesis – Terence O’Brien (Australia)
  • The role of Tau in human epilepsy – Matthias Koepp (United Kingdom)
  • The impact of seizures on Alzheimer’s – Andrew Cole (USA)